A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia

ClinicalTrials.gov ID: NCT01234779

Public ClinicalTrials.gov record NCT01234779. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Multi-center, Randomized, 4-week, Double-blind, Parallel Group, Placebo and Active-controlled Trial of the Safety and Efficacy of RO4917838 vs. Placebo in Patients With an Acute Exacerbation of Schizophrenia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This randomized, double-blind, placebo- and active-controlled, parallel group study will evaluate the safety and efficacy of RO4917838 (bitopertin) in patients with acute exacerbation of schizophrenia. Patients will be randomized to receive either RO4917838 10 mg or RO4917838 30 mg or olanzapine 15 mg or placebo orally daily for 4 weeks as inpatients, with a 4-week follow-up period.

Study identification

NCT ID: NCT01234779
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Hoffmann-La Roche; Industry
Enrollment: 301 participants

Conditions and interventions

Conditions

Schizophrenia

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 2011 (Type not available)
Primary completion: Sep 2012 (Actual)
Completion: Sep 2012 (Actual)
Last update posted: Nov 2, 2016

2011 – 2012

United States locations

U.S. sites: 19
U.S. states: 13
U.S. cities: 19

Facility	City	State	ZIP	Site status
Not listed	Little Rock	Arkansas	72201	—
Not listed	Cerritos	California	90703	—
Not listed	Oceanside	California	92056	—
Not listed	Pico Rivera	California	90660	—
Not listed	San Diego	California	92121	—
Not listed	Lauderhill	Florida	33021	—
Not listed	North Miami	Florida	33161	—
Not listed	Atlanta	Georgia	30308	—
Not listed	Lake Charles	Louisiana	70601	—
Not listed	Flowood	Mississippi	39232	—
Not listed	St Louis	Missouri	63141	—
Not listed	Willingboro	New Jersey	08046	—
Not listed	Holliswood	New York	11423	—
Not listed	New York	New York	11004	—
Not listed	Cincinnati	Ohio	45219	—
Not listed	Philadelphia	Pennsylvania	19139	—
Not listed	Charlesston	South Carolina	29405	—
Not listed	Austin	Texas	78754	—
Not listed	Irving	Texas	75062	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01234779, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 2, 2016 · Synced Oct 23, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01234779 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →